A non‐covalent inhibitor XMU‐MP‐3 overrides ibrutinib‐resistant BtkC481S mutation in B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14809
Abstract: Bruton's tyrosine kinase (BTK) plays a key role in B‐cell receptor signalling by regulating cell proliferation and survival in various B‐cell malignancies. Covalent low‐MW BTK kinase inhibitors have shown impressive clinical efficacy in B‐cell malignancies.… read more here.
Keywords: resistant btkc481s; btkc481s mutation; cell malignancies; ibrutinib resistant ... See more keywords